Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111M
-
Number of holders
-
229
-
Total 13F shares, excl. options
-
92.9M
-
Shares change
-
+4.43M
-
Total reported value, excl. options
-
$1.59B
-
Value change
-
+$79.8M
-
Put/Call ratio
-
0.4
-
Number of buys
-
117
-
Number of sells
-
-112
-
Price
-
$17.13
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q2 2024
294 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q2 2024.
NovoCure Ltd - Common Stock (NVCR) has 229 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.9M shares
of 111M outstanding shares and own 83.63% of the company stock.
Largest 10 shareholders include FMR LLC (16.1M shares), BlackRock Inc. (12.1M shares), Capital International Investors (11.7M shares), VANGUARD GROUP INC (11.1M shares), STATE STREET CORP (3.01M shares), GEODE CAPITAL MANAGEMENT, LLC (2.38M shares), Capital World Investors (2.31M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.16M shares), T. Rowe Price Investment Management, Inc. (1.71M shares), and BAILLIE GIFFORD & CO (1.69M shares).
This table shows the top 229 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.